Clinical Trials Logo
  1. Home
  2. Neurofibromatosis 2
  3. NCT04283669

Phase 2 Clinical Trial of Crizotinib for Children and Adults With Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas — NF110  

Neurofibromatosis 2 Clinical Trial

Official title:
Open-label, Phase 2 Clinical Trial of Crizotinib for Children and Adults With Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas

Clinical Trial Summary

Subjects with Neurofibromatosis Type 2 (NF2) and progressive vestibular schwannoma (VS) will be treated with crizotinib administered orally. Crizotinib will be taken continuously until disease progression or unacceptable toxicity, in continuous treatment cycles of 28 days each, for a maximum of 12 cycles.

Clinical Trial Description

Subjects with Neurofibromatosis Type 2 (NF2) and progressive vestibular schwannoma (VS) will be treated with crizotinib administered orally. Crizotinib will be taken continuously until disease progression or unacceptable toxicity, in continuous treatment cycles of 28 days each, for a maximum of 12 cycles. Clinical response will be assessed by MRI (volumetrics, primary objective) and audiology at the end of every 3rd cycle. Subjects with volumetric tumor progression will be taken off protocol. Patients who complete 12 cycles of treatment without disease progression, but within the following 24 weeks show subsequent disease progression (defined as >20% increase in target tumor volume compared to off-treatment volume), will be eligible for re-treatment on study for up to 48 additional weeks, provided they still meet study eligibility criteria. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04283669
Study type Interventional
Source University of Alabama at Birmingham
Contact
Status Active, not recruiting
Phase Phase 2
Start date February 18, 2020
Completion date December 31, 2025
View Details
See also
  Status Clinical Trial Phase
Completed NCT03617276 - Reliability of Functional Outcome Measures in Neurofibromatosis 2
Active, not recruiting NCT00973739 - Lapatinib Study for Children and Adults With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors Phase 2
Completed NCT00030043 - An Implant for Hearing Loss Due to Removal of Neurofibromatosis 2 Tumors Phase 1
Recruiting NCT05685836 - 89Zr-Bevacizumab PET/CT Imaging in NF2 Patients
Completed NCT00004437 - Phase II Study of the Multichannel Auditory Brain Stem Implant for Deafness Following Surgery for Neurofibromatosis 2 Phase 2
Recruiting NCT03406208 - Resiliency Training for Adults With Neurofibromatosis Via Live Videoconferencing N/A
Active, not recruiting NCT03095248 - Trial of Selumetinib in Patients With Neurofibromatosis Type II Related Tumors Phase 2
Completed NCT02298270 - Resiliency Training for Patients With Neurofibromatosis Via Videoconferencing With Skype N/A
Recruiting NCT01885767 - Neurofibromatosis (NF) Registry Portal
Completed NCT00863122 - Concentration and Activity of Lapatinib in Vestibular Schwannomas Early Phase 1
Recruiting NCT03079999 - Study of Aspirin in Patients With Vestibular Schwannoma Phase 2
Terminated NCT00911248 - PTC299 for Treatment of Neurofibromatosis Type 2 Phase 2
Completed NCT02811718 - Resiliency Training for Patients With NF2 Via Videoconferencing With Skype N/A
Enrolling by invitation NCT04890132 - Vestibular Precision: Physiology & Pathophysiology N/A
Completed NCT01490476 - Efficacy and Safety Study of RAD001 in the Growth of the Vestibular Schwannoma(s) in Neurofibromatosis 2 (NF2) Patients Phase 2
Active, not recruiting NCT00004483 - NF2 Natural History Consortium N/A
Recruiting NCT03893643 - Cutaneous and Mucosal Manifestations of Neurofribromatosis Type 2 in Children Under 15
Completed NCT02831257 - AZD2014 In NF2 Patients With Progressive or Symptomatic Meningiomas Phase 2